There remain issues with benchmarking, attribution, and risk adjustment that CMS needs to address with accountable care organizations (ACOs), said Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System.
There remain issues with benchmarking, attribution, and risk adjustment that CMS needs to address with accountable care organizations (ACOs), said Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System.
Transcript
What are some areas for continued improvement in Medicare Shared Savings Program that CMS has not addressed yet?
I think that’s a difficult question. They’ve addressed a lot of the things in part. So, I think there are several major buckets, I think, where systems and other ACOs have concerns. One is around benchmarking. The way that CMS attributes the target price essentially for patients has been challenging and hard to predict. It is improving: things like regional benchmarking, for the most part, is a step in the right direction for most systems, but not across the board. But I think what needs to improve is the predictability. We see pretty significant swings even within the same performance year from baseline, historical benchmarks, to final, reconciled benchmarks. And I think that’s a challenge, especially when you’re talking about risk. If we’re seeing swings of as much as 10% in how the benchmark goes, that’s really difficult to predict. You could be tracking great all year, and then end up upside down in the end in a way that wasn’t predictable. So, that’s a problem and it doesn’t exist in Medicare Advantage, but it absolutely exists in these models.
I think the other piece is attribution still can be challenging. And I don’t know if there’s a perfect solution for that, whether it’s retrospective or prospective and there are models that try to address both. There are ways of perhaps reconciling attribution based on where patients are actually seen and things like that. But I think there needs to be continued work on attribution, as well.
And I think the last one, which is as important as the benchmarking piece, is ability to risk adjust throughout the performance year would be particularly helpful as the population changes. There is certainly significant churn in membership because of attribution. And not being able to adapt the risk adjustment to the new patients that are coming on is perhaps a problem.
What additional innovations would you like to see coming out of CMS?
I would really be interested in things coming out of CMMI [Center for Medicare and Medicaid Innovation] that start to look at how do we pay or how do we finance the social determinants and other nonhealthcare-related services that we all deal with. We are talking about it here at the conference this fall, many sessions discussing how we handle social determinants and how we finance that. And having models that more easily tie the delivery and coordination of those services, which is very much a part of this work, finding a way of connecting that to the financial model, I think, would be an interesting thing to try to work on. But that’s likely more of a CMMI innovation process rather than a true MSSP process.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More